Galen Holdings the Craigavon-based specialty pharmaceutical company, today reported a 118 per cent rise in second quarter revenues to £46.7 million sterling.
Pharmaceutical product revenue increased 202 per cent reflecting the impact of the acquisition of Warner Chilcott in September last year and its ensuing strong performance.
Earnings per share rose to 6p compared to 3.7p for last year’s second quarter.
Galen’s chief executive, Mr Roger Boissonneault said "The group has once again performed strongly during the quarter, with both our product and services divisions contributing positively to the overall profitability of the group."
Earlier this year Galen raised £300 million in an open share offer. Mr Boissonneault said the funds raised have placed the company in a strong position to expand its portfolio of women's healthcare products as strategic opportunities arise.